Efficacy of Organic and Inorganic Selenium in Treatment of Bovine Subclinical Mastitis

Sripad, K.¹, Upendra, H.A.² and Yathiraj, S.³

¹Deputy Director, Institute of Animal Health & Veterinary Biologicals, Hebbal, Bangalore,
²Professor, Department of TVCC, Veterinary College, Bangalore ³Dean, Veterinary College, Bangalore

Abstract: Subclinical mastitis (SCM) could only be diagnosed by laboratory examination since it is bereft of any gross inflammatory changes. Treatment of SCM in dairy cows plays a major role in dairy industry. Researchers have tried antibiotics/antibacterials either alone or with supportive therapy. Among the supportive treatments adopted, Vitamin E and selenium tops the list. The present study is taken up to evaluate the efficacy of organic and inorganic selenium with/without Enrofloxacin, in the treatment of SCM. Twentyfour cows which were positive for SCM, randomly allocated into four treatment groups of six animals each - Group I(control), Group II(Enrofloxacin) Group III(Enrofloxacin+inorganic selenium) and Group IV(Enrofloxacin+organic selenium) were used for the study. Response to treatment using Somatic Cell Count(SCC), was studied up to 120 days. Mean SCC on different days of PT within each treatment group revealed significant decrease (P ≤ 0.05) from zero day. As compared to all the three treatment groups, mean SCC was lowest and also prolonged upto 90th day PT (less than 5 Lakh/ml ), in the group treated with organic selenium. This indicated that oral organic selenium along with Enrofloxacin, is more efficacious and beneficial in the treatment of SCM in dairy cows.

Keywords: Bovine subclinical mastitis, Efficacy, Inorganic, Organic, selenium.

I. Introduction

Mastitis, an inflammation of the mammary gland, remains as a serious problem in dairy industry since several decades and more so is the SCM. Occurrence of mastitis depends on the interaction of host, agent and environmental factors. Improvisation of dairy industry in terms of quality and quantity of milk produced is threatened by mastitis, which continues to be a cause of significant economic loss to the dairy industry not only in India, but also globally.

Clinical mastitis represents only the ‘tip of the iceberg’ and it is the significance of the sub-clinical mastitis that is frequently underestimated. SCM is considered economically the most important infection / disease in dairy herds, affecting 20 per cent to 50 per cent of cows in given herds [1,2]. Although the loss due to SCM is difficult to quantify, most experts agree that it costs the average dairy farmer more than the clinical mastitis does [3]. As there are no gross inflammatory changes either in the cow or udder or the milk, SCM could only be diagnosed by laboratory examination.

Treatment of SCM in dairy cows plays a major role in dairy industry. Researchers have tried antibiotics or antibacterials either alone or in combination and further with supportive or additional chemotherapeutic agents (anti inflammatory drugs, vitamins, etc.,) or chemicals. In addition to the treatment of mastitis with antibiotic/antibacterial, in order to hasten recovery, to trigger immune response or to ensure 100 per cent normalcy, supportive therapy have been advocated by veterinary practitioners. Among the supportive treatments adopted in the treatment of mastitis, Vitamin E and selenium tops the list. Over a period of time, researchers have undermined the information regarding activity, metabolism and beneficial effects of organic and inorganic selenium. Keeping this in mind, the present study is taken up to evaluate and compare the efficacy of organic and inorganic selenium along with a single chemotherapeutic agent (Enrofloxacin) for the treatment of SCM in dairy cows.

II. Material and Methods

2.1. Source of animals :

Twentyfour cows which were detected positive for SCM and randomly allocated into four groups namely Group I, Group II, Group III and Group IV, with each group comprising of six animals, formed the source of animals for the study.

2.2. Therapeutic agents used in the study :

Enrofloxacin – Floxidin K – obtained from M/s.Intervet India Pvt. Ltd., Pune
Inorganic selenium - procured from M/s. Vet Care Pvt. Ltd., Bangalore
Organic selenium - procured from Indian Herbs Pvt. Ltd., Bangalore
2.3. Treatment Regimens:

The following regimens of treatment was followed for different groups -

Group I: Control Group
Group II: Enrofloxacin @ 5 mg/Kg body weight Intramuscular s.i.d for five days.
Group III: Enrofloxacin @ 5 mg/Kg body weight Intramuscular s.i.d for five days and inorganic selenium @ 6 mg / animal / day orally for five days.
Group IV: Enrofloxacin @ 5 mg/Kg body weight Intramuscular s.i.d for five days and organic selenium @ 0.3 mg / animal / day orally for five days.

2.4. Laboratory Analysis:

Response to the treatment using SCC, was studied by collecting milk samples from all the twentyfour cows belonging to four groups namely Group I, Group II, Group III and Group IV, on zero, 4th, 8th, 15th, 30th, 45th, 60th, 75th, 90th, 105th and 120th day PT.

2.5. Somatic Cell Count (SCC):

Somatic Cell Count was estimated using Nucleocounter (Chemo Metec, Denmark) following the instructions given by the manufacturer.

2.6. Statistical Analysis:

The data generated in the study were statistically analyzed by Student’s ‘t’ test and one way ANOVA at P ≤ 0.05, by using statistical software, to arrive at the conclusion.

III. Results

The mean SCC of each group on different days of PT are given in Table 1. On observation the mean SCC within Group I(control group) ranged between 7.63 Lakh/ml to 21.17 Lakh/ml with lot of variations and no definite pattern. In Group II (Enrofloxacin alone), PT mean SCC decreased from a base value of 14.35 to a lowest value of 2.45 Lakh/ml on 8th day PT, later increased without any definite pattern and remained in the range between 2.45 Lakh/ml to 6.67 Lakh/ml. In Group III (Enrofloxacin with inorganic selenium) PT mean SCC decreased from a base value of 16.46 Lakh/ml to a lowest value of 2.22 Lakh/ml on 8th and 15th day PT, later increased without any definite pattern and remained in the range between 2.22 Lakh/ml to 6.24 Lakh/ml. In Group IV (Enrofloxacin with organic selenium), there was a definite drop in the PT mean SCC from a base value of 14.92 Lakh/ml (zero day) and the lowest mean SCC of 1.62 Lakh/ml was recorded on 15th day PT, then it increased gradually along with the subsequent collections and reached a maximum of 6.83 Lakh/ml on 120th day.

Statistical comparison of mean SCC on different days of PT within each treatment group revealed significant decrease (P ≤ 0.05) from the base value viz., zero day, in all the three treatment groups, whereas the control group mean SCC did not reveal any significant difference (P ≥ 0.05). This indicated that all the three treatments when compared to the control group, resulted in significant reduction (P ≤ 0.05) of mean SCC from 4th day PT till the end of the experiment i.e., 120 days.

On comparison of mean SCC between the groups, there was no statistically significant difference on Zero day (P ≥ 0.05). However, the mean SCC of Group II (Enrofloxacin), Group III (Enrofloxacin + inorganic selenium) and Group IV (Enrofloxacin + organic selenium) differed significantly (P ≤ 0.05) from Group I (control) on 4th, 8th, 15th, 30th and 45th day PT and were statistically lower in Group II (Enrofloxacin), Group III (Enrofloxacin + inorganic selenium) and Group IV (Enrofloxacin + organic selenium). At the same time there was no statistically significant difference (P ≥ 0.05) between Group II (Enrofloxacin), Group III (Enrofloxacin + inorganic selenium) and Group IV (Enrofloxacin + organic selenium), during this period. On 60th day PT mean SCC in Group IV was significantly lower (P ≤ 0.05) than Group II (Enrofloxacin) and Group III (Enrofloxacin + inorganic selenium). No statistically significant difference (P ≥ 0.05) was noticed in the mean SCC of control and different treatment groups on 75th, 90th, 105th and 120th day PT.

When SCC of more than 5 Lakh/ml was considered positive for SCM [4], it was observed that Enrofloxacin alone resulted in SCC less than 5 Lakh/ml up to 30th day PT, Enrofloxacin + inorganic selenium resulted in SCC lower than 5 Lakh/ml up to 60th day PT, whereas Enrofloxacin + organic selenium treatment resulted in SCC lower than 5 Lakh/ml up to 90th day PT. This indicated that therapeutic effect of Enrofloxacin + organic selenium was highest followed by Enrofloxacin + inorganic selenium and Enrofloxacin alone in descending order. Oral organic selenium as an additional therapeutic agent resulted in a prolonged reduction of SCC as compared to antibacterial therapy alone.
In the group that was treated with Enrofloxacin (Group II), Enrofloxacin + inorganic selenium (Group III) and Enrofloxacin + organic selenium (Group IV), mean SCC reduced significantly as compared to the control group (Group I). When mean SCC of Group II, Group III and Group IV was compared, there was no significant difference in mean SCC up to 45th day PT. The lowest mean SCC observed was 2.45, 2.22 and 1.62 Lakhs/ml respectively in Enrofloxacin, Enrofloxacin + inorganic selenium and Enrofloxacin + organic selenium treated group.

In Group II (Enrofloxacin), Group III (Enrofloxacin + inorganic selenium) and Group IV (Enrofloxacin + organic selenium), the mean SCC reduced below 5 Lakhs/ml as early as 4th day PT. Further reduction in mean SCC was noticed for an extended period in Enrofloxacin + organic selenium treated group (Group IV) followed by Enrofloxacin + inorganic selenium (Group III) and Enrofloxacin (Group II) treated group in the descending order. The mean SCC was significantly reduced (below 5 lakhs/ml) up to 30th, 60th and 90th days PT in Enrofloxacin (Group II), Enrofloxacin + inorganic selenium (Group III) and Enrofloxacin + organic selenium (Group IV) groups respectively. The mean SCC was significantly lower in Group IV (Enrofloxacin + organic selenium) as compared to other two treatment groups on 60th day PT.

It was noticed that the therapeutic efficacy of Enrofloxacin along with organic selenium (Group IV) was more prolonged as compared with the group treated only with Enrofloxacin (Group II) or group treated with Enrofloxacin + inorganic selenium (Group III).

The results of the present study indicated that treatment with Enrofloxacin (Group II), Enrofloxacin + inorganic selenium (Group III) and Enrofloxacin + organic selenium (Group IV) resulted in therapeutic recovery in cases of SCM in dairy cows. It was noticed that therapeutic efficacy was better when selenium (inorganic or organic) was combined with Enrofloxacin. Further, organic selenium with Enrofloxacin exhibited comparatively much better therapeutic recovery than the other two treatment groups.

The observation of reduced mean SCC following treatment during lactation period is in agreement with the observation made by earlier workers namely [5,6,7].

Treatment of SCM with Enrofloxacin alone resulted in significant reduction in mean SCC. This indicates Enrofloxacin can be an antibacterial of choice in the treatment of SCM in dairy cows. This observation is in agreement with the findings of [8,9,10,11,12,13,14, 15]

When organic selenium and inorganic selenium were administered orally along with parental Enrofloxacin, these two treatment regimens resulted in lowered mean and their effect was noticed for prolonged period as compared to group treated with Enrofloxacin alone (Group II). This indicates that oral administration of selenium (organic selenium or inorganic selenium) is beneficial in treatment of SCM in dairy cows.

The beneficial therapeutic effect of inorganic selenium observed in the present study derives support from the findings of [16] who has reported that inorganic selenium is beneficial in treatment of SCM. However, [17] failed to observe the beneficial effects of Vitamin E and selenium in decreasing SCC. The beneficial effects of administration of inorganic selenium in treatment of SCM in dairy cows could be attributed to the antioxidant property, increased glutathione peroxidase activity, increased conversion of T3 to active T3 form of Thyroxine as indicated by [18].

Further, administration of organic selenium resulted in reduction of mean SCC for a prolonged period up to 90th day PT as compared to 60th day PT in cows treated with inorganic selenium, indicating organic selenium has better therapeutic effect in the treatment of SCM in dairy cows as compared to inorganic selenium. Organic selenium supplementation along with antibacterial resulted in reduction in SCC [19]. Organic selenium, as compared to inorganic selenium is reported to have better bioavailability [20]. Further organic selenium improves the bactericidal activity of neutrophils [21,22] and has a role in enhancing the resistance of mammary gland to infection [23]. Organic selenium also plays a role in boosting the immune response of the body thus improving general health status of animals [24, 25]. In addition, organic selenium induces self cure of SCM and decreases the prevalence of SCM by recruiting phagocytes to the infected compartment of the udder and induces an unspecified antibactericidal activity in milk lactoserum [26]. (Ali Vehmas et al., 1997). Organic selenium also restricts the growth of mastitis causing pathogens, lowers SCC in milk and results in high milk quality [18]. In view of these properties, organic selenium as a supportive therapy seems to be beneficial in the treatment of SCM in dairy cows.

V. Conclusion

Based on the results of the study, we can conclude that Enrofloxacin + organic selenium, Enrofloxacin + inorganic selenium and Enrofloxacin alone, can be the order of preference or choice for treatment of SCM in dairy cows. Enrofloxacin with organic selenium is the treatment of choice for treatment of SCM among dairy cows.
Table 1. Mean ± SE of SCC in different treatment groups

<table>
<thead>
<tr>
<th>PT days of collection</th>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
<th>Group IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zéro</td>
<td>¹15.44±2.90 ² ḥ</td>
<td>¹14.35±2.69 ² ḥ</td>
<td>³16.46±3.67 ³ ḥ</td>
<td>⁴14.92±3.54 ⁴ ḥ</td>
</tr>
<tr>
<td>4</td>
<td>¹13.34±1.94 ² ḥ</td>
<td>²2.92±0.48 ³ ḥ</td>
<td>³2.52±0.32 ⁴ ḥ</td>
<td>⁴2.32±0.27 ⁴ ḥ</td>
</tr>
<tr>
<td>8</td>
<td>¹14±2.54 ² ḥ</td>
<td>²2.45±0.39 ³ ḥ</td>
<td>³2.22±0.25 ⁴ ḥ</td>
<td>⁴1.84±0.28 ⁴ ḥ</td>
</tr>
<tr>
<td>15</td>
<td>¹15.09±2.54 ² ḥ</td>
<td>²2.92±0.48 ³ ḥ</td>
<td>³2.22±0.25 ⁴ ḥ</td>
<td>⁴1.62±0.23 ⁴ ḥ</td>
</tr>
<tr>
<td>30</td>
<td>¹14.33±2.77 ² ḥ</td>
<td>³4.25±0.61 ³ ḥ</td>
<td>³2.90±0.31 ⁴ ḥ</td>
<td>⁴2.06±0.20 ⁴ ḥ</td>
</tr>
<tr>
<td>40</td>
<td>¹20.27±4.27 ² ḥ</td>
<td>³5.44±0.33 ³ ḥ</td>
<td>³4.44±0.32 ⁴ ḥ</td>
<td>⁴2.09±0.20 ⁴ ḥ</td>
</tr>
<tr>
<td>60</td>
<td>¹10.02±2.95 ² ḥ</td>
<td>³5.10±0.22 ³ ḥ</td>
<td>³4.88±0.46 ³ ḥ</td>
<td>⁴3.28±0.38 ⁴ ḥ</td>
</tr>
<tr>
<td>75</td>
<td>²7.63±3.82 ³ ḥ</td>
<td>³5.17±0.27 ³ ḥ</td>
<td>³5.20±0.19 ⁴ ḥ</td>
<td>⁴7.01±0.42 ⁴ ḥ</td>
</tr>
<tr>
<td>90</td>
<td>¹19.45±12.07 ² ḥ</td>
<td>³5.10±0.40 ³ ḥ</td>
<td>³5.34±0.16 ⁴ ḥ</td>
<td>⁴4.68±0.34 ⁴ ḥ</td>
</tr>
<tr>
<td>105</td>
<td>¹21.17±14.14 ² ḥ</td>
<td>³4.51±0.49 ³ ḥ</td>
<td>³4.84±0.39 ³ ḥ</td>
<td>⁴5.30±0.26 ⁴ ḥ</td>
</tr>
<tr>
<td>120</td>
<td>¹19.50±9.96 ² ḥ</td>
<td>³6.67±0.44 ³ ḥ</td>
<td>³6.24±0.37 ⁴ ḥ</td>
<td>⁴6.83±0.20 ⁴ ḥ</td>
</tr>
</tbody>
</table>

References


Fig. 1. Mean SCC in different treatment groups (Enrofloxacin with / without selenium)